TargetBeta
BCL11A
BCL11 transcription factor A · also BCL11A-XL, BCL11A-L, BCL11A-S, CTIP1 · Zinc fingers C2H2-type
1 program in company-led studies act on BCL11A, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| exagamglogene autotemcelrule | Vertex Pharmaceuticals | phase 3 | 96 running | – | ChEMBL |
Conditions their studies are in
- Anemia, 1 program
- Anemia, Sickle Cell, 1 program
- beta-Thalassemia, 1 program
- Renal Insufficiency, Chronic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 6, 2027exagamglogene autotemcel · Vertex Pharmaceuticals · phase 3 · NCT05329649
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.